About MethylGene Inc.

MethylGene (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease.

MGCD265 - Oncology

MGCD265 targets the Met and VEGF kinases, which appear to play key roles in tumor development, blood vessel formation (angiogenesis) and tumor survival.

MGCD290 - Antifungal

MethylGene has developed MGCD290 to enhance the activity and spectrum of current azole treatments against fungal pathogens.

Latest News.

May 14, 2012

METHYLGENE REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL PROGRAMS

Read more »
Recent releases »

Webcast.

Upcoming Event.

June 1-5, 2012, Chicago
2012 ASCO Annual Meeting

Latest Poster Presentations.


ASCO Webcast.


About MethylGene.
Our Products.
Investor Relations.

Search

Disclaimer | © MethylGene, 2004-2011.
Website design: Solo Communications